How many institutional investors hold PRME?

4 tracked institutional investors disclosed a position in PRME (PRIME MEDICINE INC) in their most recent 13F filing.

Who is the largest institutional holder of PRME?

Cathie Wood, ARK Investment Management, holds the largest disclosed position in PRME, valued at $30M.

Where does this PRME ownership data come from?

SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.

PRME — PRIME MEDICINE INC

Name: PRIME MEDICINE INC (PRME) — Institutional Ownership
Creator: InvestorLens
License: https://www.sec.gov/about/website-policies

Public company

For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About PRIME MEDICINE INC (PRME)

PRIME MEDICINE INC (PRME) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Cathie Wood (ARK Investment Management), valued at $30M. Across recent filings, tracked investors recorded 1 new positions, 1 increased, 1 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in PRME

/100

Mixed Activity

Added / Increased2

Reduced1

Exited1

BearishBullish

Crowded Trade Score™

How many top investors track PRME

/100

Emerging Interest

4investors

A small number of top investors own this.

UndiscoveredCrowded

151015+

PRME Ownership Composition

How PRIME MEDICINE INC is held across tracked investor types, based on reported 13F positions.

Dominant Type

Growth Funds

84% of tracked value

Institutions

tracked investors

Total Reported

$25.9M

combined 13F value

Growth Funds83.9%
Other8.7%
Hedge Funds7.4%

Growth Funds(1)

83.9%

Other(2)

8.7%

Hedge Funds(1)

7.4%

Tracked investors reporting PRME

Investor	Firm	Shares	Market value	% of portfolio	As of
Cathie Wood	ARK Investment Management	6.2M	$21.7M	0.17%	Mar 31, 2026
Ken Griffin	Citadel Advisors	598.1K	$2.1M	0.00%	Mar 31, 2026
Steve Cohen	Point72 Asset Management	551K	$1.9M	0.00%	Dec 31, 2025
Izzy Englander	Millennium Management	51.3K	$178.1K	0.00%	Dec 31, 2025

Cathie WoodMar 31, 2026
ARK Investment Management
Shares
6.2M
Value
$21.7M
% Portfolio
0.17%
Ken GriffinMar 31, 2026
Citadel Advisors
Shares
598.1K
Value
$2.1M
% Portfolio
0.00%
Steve CohenDec 31, 2025
Point72 Asset Management
Shares
551K
Value
$1.9M
% Portfolio
0.00%
Izzy EnglanderDec 31, 2025
Millennium Management
Shares
51.3K
Value
$178.1K
% Portfolio
0.00%

Recent activity

Investor	Action	Δ %	Current value	Filing date
Cathie Wood	Increased	16.36%	$21.7M	May 12, 2026
Ken Griffin	Sold	-100.00%	$0	Feb 17, 2026
Cathie Wood	Reduced	-2.00%	$18.6M	Feb 11, 2026
Cathie Wood	New	—	$30.3M	Nov 12, 2025

Cathie Wood
Increased
$21.7M(16.36%)May 12, 2026
Ken Griffin
Sold
$0(-100.00%)Feb 17, 2026
Cathie Wood
Reduced
$18.6M(-2.00%)Feb 11, 2026
Cathie Wood
New
$30.3MNov 12, 2025

Frequently asked questions

How many institutional investors hold PRME?: 4 tracked institutional investors disclosed a position in PRME (PRIME MEDICINE INC) in their most recent 13F filing.
Who is the largest institutional holder of PRME?: Cathie Wood, ARK Investment Management, holds the largest disclosed position in PRME, valued at $30M.
Did institutional ownership of PRME increase or decrease?: Across recent 13F filings, tracked investors recorded 1 new positions, 1 increased, 1 reduced, and 1 fully exited PRME.
Where does this PRME ownership data come from?: SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.